Clinical trials: Neoplasm Recurrence
Recurrent Brain Tumors, Supratentorial PNETs
Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children
The purpose of this study is to improve overall survival while maintaining a good quality of life in pediatric patients with refractory or recurrent brain tumors (medulloblastomas, supratentorial PNETs, ependymomas WHO grade II…
- Conditions
- Recurrent Brain Tumors, Supratentorial PNETs, Medulloblastomas, Ependymomas
- Trial name
- HIT-REZ-2005 (NCT00749723)
- Testing
- carboplatin, etoposide, temozolomide
- Where
- 54 sites in Germany
- Volunteers
- 174 people
- Sponsor
- University Hospital, Bonn
High Risk Prostate Carcinoma, Biochemically Recurrent Prostate Carcinoma
Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System
This study is designed to evaluate the presence and numbers of circulating tumor cells (CTCs) and cancer related gene expression levels in subjects with localized high-risk prostate cancer (HRLPC) and from subjects with…
- Conditions
- High Risk Prostate Carcinoma, Biochemically Recurrent Prostate Carcinoma, Castration-resistant Prostate Cancer, Prostate Cancer
- Trial name
- CHARTER (NCT05437679)
- Testing
- Blood collection
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Angle plc
Pericarditis, Recurrence
Study of Colchicine to Treat and Prevent Recurrent Pericarditis After Failure of Conventional Treatment.
The purpose of the study is to determine whether colchicine is safe and effective in treatment and prevention of recurrent pericarditis after failure of conventional treatment.
- Trial name
- CORP 2 (NCT00235079)
- Testing
- Colchicine
- Where
- 4 sites in Italy
- Volunteers
- 240 people
- Sponsor
- Azienda Sanitaria Locale 3, Torino
Acute Lymphoblastic Leukemia
Administration of Allogenic Red Blood Cells Loaded L-asparaginase in Cases of Relapse of Acute Lymphoblastic Leukaemia
Primary objective : To explore the relation between 3 doses of GRASPA and duration of asparagine depletion (< 2µmol/l) Secondary objective : Pharmacokinetic / Pharmacodynamic parameters toxicity Study duration : 2 years Study…
- Trial name
- GRASPALL (NCT00723346)
- Testing
- GRASPA, native L asparaginase
- Where
- France
- Volunteers
- 25 people
- Sponsor
- ERYtech Pharma
Breast Cancer
(Oncotype DX®) in Estrogen Receptor Positive (ER+) HER-2 Negative (HER 2-) 1-3 Node Positive (pN1) Breast Cancer
This study is a multi-center BCCA study that evaluates the impact of the Oncotype DX® assay on the decision making of the treating physician and the patient.
- Trial name
- NCT02627703
- Testing
- Oncotype DX
- Where
- Canada
- Volunteers
- 80 people
- Sponsor
- British Columbia Cancer Agency
Colorectal Cancer Recurrent
Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer
The efficacy and safety of the use of Camrelizumab combined with Apatinib
- Trial name
- NCT04067986
- Testing
- Camrelizumab, Apatinib
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Zhongshan Hospital Xiamen University
Smoking ( Cigarette), Breastfeeding
Prevention of Postpartum Smoking Relapse and Related Health Consequences by Breastfeeding Promotion
The objective of this randomized controlled trial is to examine the efficacy of a new intervention to prevent postpartum smoking relapse and related health consequences through breastfeeding promotion.
- Trial name
- NCT07661550
- Testing
- Breastfeeding promotion
- Where
- United States
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- State University of New York at Buffalo
Alcoholism
Medication Development in Alcoholism: Investigating PPAR Agonists
The primary hypotheses under test are that alcohol dependent subjects treated with fenofibrate will report decreased craving for alcohol following cue-exposure in the laboratory and report less drinking post treatment relative to…
- Trial name
- NCT02158273
- Testing
- Sugar Pill, TRICOR (fenofibrate)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- The Scripps Research Institute
Hematopoietic Malignancy, Relapse/Recurrence
TBI/Flu/Bu/Mel Combined With Secondary UCBT in Patients With Hematological Malignancies Who Relapsed After Allo-HSCT
About 33% of patients with myeloid or lymphoid malignancies experience relapse with HLA loss after haplo-HSCT. Due to the specificity of HLA-loss relapse, the 2019 European Society for Blood and Marrow Transplantation (EBMT)…
- Conditions
- Hematopoietic Malignancy, Relapse/Recurrence, Hematopoietic Stem Cell Transplantation
- Trial name
- NCT06125483
- Testing
- Umbilical Cord Blood Transplantation
- Where
- China
- Volunteers
- 38 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Head and Neck Cancer, Recurrent Cancer
Safety and Superiority of Penicillamine in Radiosensitization of Recurrent Head and Neck Cancer
Our preclinical study confirmed that copper accumulation can lead to radioresistance in vitro and in vivo, and reducing the concentration of copper with copper chelator help to overcome radioresistance.
- Trial name
- NCT06103617
- Testing
- Penicillamine
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Recurrent Prostate Cancer
Fluorine F 18 Sodium Fluoride PET/CT and Whole Body and Axial MRI in Finding Metastases in Patients With Recurrent Prostate Cancer
This phase II trial studies how well fluorine F 18 sodium fluoride positron emission tomography (PET)/computed tomography (CT) and whole body and axial magnetic resonance imaging (MRI) work in finding metastases in patients with…
- Trial name
- NCT01967862
- Testing
- computed tomography, bone scan, 3-Tesla magnetic resonance imaging
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- City of Hope Medical Center
Inflamatory Bowel Disease, Crohn Disease (CD)
Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease
This retrospective cohort study aims to compare the efficacy of different biologics in preventing postoperative endoscopic recurrence in Crohn's disease (CD).
- Trial name
- NCT07694674
- Testing
- Infliximab, Adalimumab, Vedolizumab
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Shanghai 10th People's Hospital
Breast Cancer
Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer
This study is investigating the effects of an experimental drug (neratinib) in combination with paclitaxel versus trastuzumab in combination with paclitaxel for the treatment of women who have not received previous treatment for…
- Trial name
- NEFERTT (NCT00915018)
- Testing
- Neratinib, Trastuzumab, Paclitaxel
- Where
- 195 sites in United States, Australia and 33 more
- Volunteers
- 479 people
- Sponsor
- Puma Biotechnology, Inc.
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
This phase II trial studies how well ixazomib and rituximab work in treating patients with mantle cell lymphoma that has come back (relapsed) or does not respond (refractory) to BTK inhibitor treatment.
- Trial name
- NCT04047797
- Testing
- Ixazomib, Ixazomib Citrate, Rituximab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Brain and Central Nervous System Tumors
CCI-779 in Treating Patients With Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of CCI-779 in treating patients who have malignant…
- Trial name
- NCT00022724
- Testing
- temsirolimus
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Ovarian Cancer
Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma
Topotecan and gemcitabine are drugs globally registered for recurrent ovarian carcinoma. This trial will determine the maximum tolerated dose and the efficacy of this combination administered weekly in patients with platinum…
- Trial name
- NCT00429559
- Testing
- Hycamptin, Gemcitabine
- Where
- 6 sites in Greece
- Volunteers
- 31 people
- Sponsor
- Hellenic Oncology Research Group
Brain Metastases, Lung Cancer
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics (PK) of 2B3-101 both as single agent and in combination with trastuzumab.
- Conditions
- Brain Metastases, Lung Cancer, Breast Cancer, Melanoma
- Trial name
- NCT01386580
- Testing
- 2B3-101, Trastuzumab, 2B3-101 60 mg/m2 every 4 weeks
- Where
- 10 sites in United States, Belgium and 2 more
- Volunteers
- 84 people
- Sponsor
- BBB-Therapeutics B.V.
Recurrent Glioblastoma Multiforme, Malignant Glioma
Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients
It has been shown that bevacizumab has significant anti-tumor activity in patients with recurrent glioblastoma multiforme. Vorinostat has modest anti-tumor activity against malignant glioma and can enhance the action of both…
- Conditions
- Recurrent Glioblastoma Multiforme, Malignant Glioma, Adult Brain Tumor
- Trial name
- NCT01738646
- Testing
- Vorinostat, Bevacizumab
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Duke University
Small Intestine Adenocarcinoma, Recurrent Small Intestine Cancer
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
This phase II trial studies how well giving irinotecan hydrochloride together with oxaliplatin and capecitabine works as first-line therapy in treating patients with metastatic or unresectable locally advanced small bowel cancer.
- Trial name
- NCT00433550
- Testing
- capecitabine, irinotecan hydrochloride, oxaliplatin
- Where
- 115 sites in United States
- Volunteers
- 33 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer
Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer
T cell activating therapy DPX-Survivac, low dose oral cyclophosphamide, and IDO1 inhibitor epacadostat will be tested together for the first time in patients with recurrent ovarian, fallopian tube, or peritoneal cancer to…
- Conditions
- Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Peritoneal Cancer
- Trial name
- NCT02785250
- Testing
- DPX-Survivac, Cyclophosphamide, Epacadostat (INCB024360)
- Where
- 9 sites in United States, Canada
- Volunteers
- 85 people
- Sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.